Data gathered: November 23
AI Stock Analysis - Merck & Company (MRK)
Analysis generated November 3, 2024. Powered by Chat GPT.
Merck & Co., Inc. (NYSE: MRK), known as Merck in the United States and Canada, is a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. The company aims to make a difference in the lives of people globally through its comprehensive portfolio and pipeline of products that address various diseases and conditions.
Stock Alerts - Merck & Company (MRK)
 |
Merck & Company | November 15 Michael McCaul (member of U.S. congress) is selling shares |
|
Merck & Company | November 14 Job postings are down by -40.2% in the last couple of days. |
|
Merck & Company | November 12 Ro Khanna (member of U.S. congress) is buying shares |
|
Merck & Company | November 11 Job postings are down by 26.9% in the last couple of days. |
Alternative Data for Merck & Company
About Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.
| Price | $99.18 |
| Target Price | Sign up |
| Volume | 14,030,000 |
| Market Cap | $253B |
| Year Range | $96.31 - $132.1 |
| Dividend Yield | 3.24% |
| PE Ratio | 20.89 |
| Analyst Rating | 76% buy |
| Industry | Drug Manufacturers |
In the news
 |
Merck & Co., Inc. (MRK) Jefferies London Healthcare ConferenceNovember 20 - SeekingAlpha |
 |
Merck & Co., Inc. (MRK)’s Blockbuster Drugs: A Key Player in Ken Griffin’s PortfolioNovember 20 - Yahoo |
|
Jim Cramer Says Merck & Co., Inc. (MRK) Is ‘Just Way Too Hated’November 18 - Yahoo |
|
Is Merck & Co., Inc. (MRK) the Best Immunotherapy Stock to Buy Now?November 17 - Yahoo |
 |
The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The BusinessNovember 15 - Yahoo |
Wolfe Research Initiates Coverage of Merck (MRK) with Peer Perform RecommendationNovember 14 - Fintel |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 16.7B | 6.71B | 9.95B | 3.16B | 4.09B | 1.570 |
| Q2 '24 | 16.1B | 6.41B | 9.71B | 5.46B | 7.33B | 2.280 |
| Q1 '24 | 15.8B | 5.99B | 9.79B | 4.76B | 6.74B | 2.070 |
| Q4 '23 | 14.6B | 9.62B | 5.01B | -1.23B | 679M | 0.030 |
| Q3 '23 | 16B | 6.77B | 9.19B | 4.75B | 7.2B | 2.130 |
Insider Transactions View All
| Davis Robert M filed to sell 348,327 shares at $125.4. February 15 '24 |
| Litchfield Caroline filed to sell 50,908 shares at $125.5. February 15 '24 |
| Romanelli Joseph filed to sell 19,569 shares at $124.9. February 14 '24 |
| Davis Robert M filed to sell 348,327 shares at $126.4. February 15 '24 |
| Davis Robert M filed to sell 373,651 shares at $125.7. February 15 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$155.17 0% | 51 |
 |
Eli Lilly and CompanyLLY |
$748.01 0% | 65 |
 |
PfizerPFE |
$25.65 0% | 42 |
 |
AstrazenecaAZN |
$65.63 0% | 70 |
 |
AbbVieABBV |
$176.95 0% | 59 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Michael McCaul |
Nov 14, 24 | Sell | $1K - $15K |
| Ro Khanna |
Nov 11, 24 | Buy | $1K - $15K |
| Jonathan Jackson |
Oct 14, 24 | Sell | $15K - $50K |
Read more about Merck & Company (MRK) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Merck & Company?
The Market Cap of Merck & Company is $253B.
What is Merck & Company's PE Ratio?
As of today, Merck & Company's PE (Price to Earnings) ratio is 20.89.
What is the current stock price of Merck & Company?
Currently, the price of one share of Merck & Company stock is $99.18.
How can I analyze the MRK stock price chart for investment decisions?
The MRK stock price chart above provides a comprehensive visual representation of Merck & Company's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Merck & Company shares. Our platform offers an up-to-date MRK stock price chart, along with technical data analysis and alternative data insights.
Does MRK offer dividends to its shareholders?
Yes, Merck & Company (MRK) offers dividends to its shareholders, with a dividend yield of 3.24%. This dividend yield represents Merck & Company's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Merck & Company in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Merck & Company?
Some of the similar stocks of Merck & Company are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.